Evaluating RB1 and p53 as diagnostic markers in treatment-related neuroendocrine prostate cancer through immunohistochemistry and genomic analysis of RB1 and TP53.

Hideto UekiNaoe JimboTomoaki Terakawa Takuto HaraTaisuke TobeJunichiro HirataNaoto WakitaYasuyoshi OkamuraKotaro SuzukiYukari BandoKoji ChibaJun TeishimaYuzo NakanoHideaki Miyake

Published in: The Prostate (2024)

This study indicated high concordance between IHC and NGS findings for RB1/RB1 and p53/TP53 in t-NEPC. We provide a comprehensive benchmark of NGS performance compared with IHC, and these findings may help increase the diagnostic sensitivity of t-NEPC.

Keyphrases

prostate cancer
radical prostatectomy
combination therapy
drug induced